Half-Life Reference
Look up elimination half-lives, time to steady state, and dosing frequency for common compounds.
Half-life values are approximate. Many research compounds lack formal human pharmacokinetic studies. Estimated values are noted. This is reference data, not dosing guidance.
| AOD-9604 | ~1–2 hours (estimated)Estimated — limited human PK data available. | ~6–10 hoursEstimated — limited human PK data available. | Once daily |
| BPC-157 | ~4 hours | ~20 hours | 1–2× daily |
| CJC-1295 (DAC) | ~8 days | ~4–5 weeks | 1–2× weekly |
| CJC-1295 (no DAC / Mod GRF) | ~30 minutes | ~2.5 hours | 1–3× daily |
| GHK-Cu | ~1–2 hours (estimated)Estimated — limited human PK data available. | ~6–10 hoursEstimated — limited human PK data available. | Once daily |
| Ipamorelin | ~2 hours | ~10 hours | 1–3× daily |
| MK-677 | ~24 hours | ~5 days | Once daily |
| NAD+ (IV) | ~30–45 minutes (plasma)Estimated — limited human PK data available. | N/A | Per protocol |
| Oxytocin | ~3–5 minutes (IV) | N/A | Per protocol |
| PT-141 | ~2–3 hours | ~12–15 hours | As needed |
| Semaglutide | ~7 days | ~4–5 weeks | Once weekly |
| Sermorelin | ~10–20 minutes | ~1–2 hours | Once daily (before bed) |
| TB-500 | ~2–3 hours (estimated)Estimated — limited human PK data available. | ~12–15 hoursEstimated — limited human PK data available. | 2× weekly (loading), 1× weekly (maintenance) |
| Tesamorelin | ~26–38 minutes | ~3 hours | Once daily |
| Tirzepatide | ~5 days | ~4–5 weeks | Once weekly |